| Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians M Allgäuer, J Budczies, P Christopoulos, V Endris, A Lier, E Rempel, ... Translational lung cancer research 7 (6), 703, 2018 | 180 | 2018 |
| Size matters: dissecting key parameters for panel‐based tumor mutational burden analysis I Buchhalter, E Rempel, V Endris, M Allgäuer, O Neumann, AL Volckmar, ... International journal of cancer 144 (4), 848-858, 2019 | 164 | 2019 |
| Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations C Menzer, AM Menzies, MS Carlino, I Reijers, EJ Groen, T Eigentler, ... Journal of Clinical Oncology 37 (33), 3142-3151, 2019 | 111 | 2019 |
| Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panels V Endris, I Buchhalter, M Allgäuer, E Rempel, A Lier, AL Volckmar, ... International journal of cancer 144 (9), 2303-2312, 2019 | 109 | 2019 |
| Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: analysis of the first 3,000 Heidelberg cases AL Volckmar, J Leichsenring, M Kirchner, P Christopoulos, O Neumann, ... International Journal of Cancer 145 (3), 649-661, 2019 | 102 | 2019 |
| Pan‐cancer analysis of copy number changes in programmed death‐ligand 1 (PD‐L1, CD274)–associations with gene expression, mutational load, and survival J Budczies, M Bockmayr, C Denkert, F Klauschen, S Gröschel, ... Genes, Chromosomes and Cancer 55 (8), 626-639, 2016 | 102 | 2016 |
| Variant classification in precision oncology J Leichsenring, P Horak, S Kreutzfeldt, C Heining, P Christopoulos, ... International Journal of Cancer 145 (11), 2996-3010, 2019 | 100 | 2019 |
| Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts D Kazdal, V Endris, M Allgäuer, M Kriegsmann, J Leichsenring, ... Journal of Thoracic Oncology 14 (11), 1935-1947, 2019 | 93 | 2019 |
| Patients resistant against PSMA-targeting α-radiation therapy often harbor mutations in DNA damage-repair–associated genes C Kratochwil, FL Giesel, CP Heussel, D Kazdal, V Endris, C Nientiedt, ... Journal of Nuclear Medicine 61 (5), 683-688, 2020 | 74 | 2020 |
| Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays N Pfarr, M Kirchner, U Lehmann, J Leichsenring, S Merkelbach‐Bruse, ... Genes, Chromosomes and Cancer 59 (3), 178-188, 2020 | 62 | 2020 |
| Taxon‐and vector‐specific variation in species richness and abundance during the transport stage of biological invasions E Briski, SA Bailey, O Casas-Monroy, C DiBacco, I Kaczmarska, ... Limnology and Oceanography 58 (4), 1361-1372, 2013 | 55 | 2013 |
| The BRCA2 mutation status shapes the immune phenotype of prostate cancer M Jenzer, P Keß, C Nientiedt, V Endris, M Kippenberger, J Leichsenring, ... Cancer Immunology, Immunotherapy 68, 1621-1633, 2019 | 48 | 2019 |
| RNA-based detection of gene fusions in formalin-fixed and paraffin-embedded solid cancer samples M Kirchner, O Neumann, AL Volckmar, F Stögbauer, M Allgäuer, D Kazdal, ... Cancers 11 (9), 1309, 2019 | 48 | 2019 |
| The value of prostate-specific antigen density for Prostate Imaging-Reporting and Data System 3 lesions on multiparametric magnetic resonance imaging: a strategy to avoid … M Görtz, JP Radtke, G Hatiboglu, V Schütz, G Tosev, M Güttlein, ... European urology focus 7 (2), 325-331, 2021 | 46 | 2021 |
| Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival P Christopoulos, S Dietz, M Kirchner, AL Volckmar, V Endris, O Neumann, ... Cancers 11 (1), 124, 2019 | 46 | 2019 |
| Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas M Bosic, M Kirchner, D Brasanac, J Leichsenring, A Lier, AL Volckmar, ... Pathology 50 (3), 327-332, 2018 | 43 | 2018 |
| Combined immunohistochemistry after mass spectrometry imaging for superior spatial information K Kriegsmann, R Longuespée, M Hundemer, C Zgorzelski, R Casadonte, ... PROTEOMICS–Clinical Applications 13 (1), 1800035, 2019 | 31 | 2019 |
| Validating comprehensive next-generation sequencing results for precision oncology: the NCT/DKTK molecularly aided stratification for tumor eradication research experience A Lier, R Penzel, C Heining, P Horak, M Fröhlich, S Uhrig, J Budczies, ... JCO Precision Oncology 2, 1-13, 2018 | 29 | 2018 |
| Targeted next‐generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance N Pfarr, R Penzel, V Endris, C Lier, C Flechtenmacher, AL Volckmar, ... Genes, Chromosomes and Cancer 56 (4), 255-265, 2017 | 29 | 2017 |
| Community-driven development of a modified progression-free survival ratio for precision oncology A Mock, CE Heilig, S Kreutzfeldt, D Huebschmann, C Heining, E Schröck, ... Esmo Open 4 (6), e000583, 2019 | 28 | 2019 |
